Beijing Konruns Pharmaceutical Co Ltd Total Assets
Beijing Konruns Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Beijing Konruns Pharmaceutical Co Ltd (603590) holds total assets worth CN¥4.08 Billion CNY (≈ $596.62 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 603590 stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Beijing Konruns Pharmaceutical Co Ltd (2013–2025)
Total assets of Beijing Konruns Pharmaceutical Co Ltd from 2013 to 2025. This chart illustrates how Beijing Konruns Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See 603590 share price today for real-time trading data and today's change.
Beijing Konruns Pharmaceutical Co Ltd - Asset Composition Analysis
Beijing Konruns Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
Beijing Konruns Pharmaceutical Co Ltd total assets breakdown as of December 2025. Beijing Konruns Pharmaceutical Co Ltd's total assets of CN¥4.08 Billion consist of 34.1% current assets and 65.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.1% |
| Accounts Receivable | CN¥272.30 Million | 6.7% |
| Inventory | CN¥54.47 Million | 1.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.14 Billion | 27.9% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Beijing Konruns Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Beijing Konruns Pharmaceutical Co Ltd (603590) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing Konruns Pharmaceutical Co Ltd's current assets represent 34.1% of total assets in 2025, an increase from 27.0% in 2013.
- Cash Position: Cash and equivalents constituted 8.1% of total assets in 2025, down from 21.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 27.0% of total assets, an increase from 23.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 27.9% of total assets.
Beijing Konruns Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Beijing Konruns Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥28.15 Billion |
Beijing Konruns Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.05 | 3.81 | 2.73 |
| Quick Ratio | 2.91 | 3.59 | 2.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥888.84 Million | CN¥879.61 Million | CN¥936.34 Million |
Beijing Konruns Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Beijing Konruns Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.76 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | 4.5% |
| Total Assets | CN¥4.09 Billion |
| Market Capitalization | $596.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Beijing Konruns Pharmaceutical Co Ltd's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Beijing Konruns Pharmaceutical Co Ltd's assets grew by 4.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Beijing Konruns Pharmaceutical Co Ltd (2013–2025)
The table below shows the annual total assets of Beijing Konruns Pharmaceutical Co Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥4.09 Billion ≈ $599.23 Million |
+4.47% |
| 2024-12-31 | CN¥3.92 Billion ≈ $573.57 Million |
+3.67% |
| 2023-12-31 | CN¥3.78 Billion ≈ $553.25 Million |
+10.40% |
| 2022-12-31 | CN¥3.42 Billion ≈ $501.16 Million |
+1.59% |
| 2021-12-31 | CN¥3.37 Billion ≈ $493.33 Million |
-10.95% |
| 2020-12-31 | CN¥3.79 Billion ≈ $553.96 Million |
+19.28% |
| 2019-12-31 | CN¥3.17 Billion ≈ $464.43 Million |
+8.69% |
| 2018-12-31 | CN¥2.92 Billion ≈ $427.32 Million |
+74.42% |
| 2017-12-31 | CN¥1.67 Billion ≈ $244.99 Million |
+63.77% |
| 2016-12-31 | CN¥1.02 Billion ≈ $149.59 Million |
+20.87% |
| 2015-12-31 | CN¥845.80 Million ≈ $123.77 Million |
+27.18% |
| 2014-12-31 | CN¥665.04 Million ≈ $97.32 Million |
+29.10% |
| 2013-12-31 | CN¥515.13 Million ≈ $75.38 Million |
-- |
About Beijing Konruns Pharmaceutical Co Ltd
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in p… Read more